| Page 117 | Kisaco Research
  • Learn about novel methods to generate large, bespoke high-resolution datasets in a matter of weeks instead of months.
  • Explore how high-throughput, high-resolution interaction kinetics can fine tune AI models resulting in more efficient workflows and improved therapeutic characteristics
  • Discover how kinetic datasets generated under multiple pH conditions can support the development of pH dependent binders for cancer therapies using AI.

Author:

Bharath Takulapalli, PhD

Founder & CEO
SPOC Biosciences

Bharath is inventor of multiple foundational life science technologies at the interface of nanotechnology, systems biology and ML/AI, to extract 100x more information from systems biology than currently possible. He conceived Sensor-integrated Proteome On Chip (SPOC) technology to bridge a big gap in proteomics space, to democratize high-throughput functional protein screening. SPOC is the first and only technology that enables production of 1000s of full-length folded proteins on 1.5 sq-cm biosensor chips, to simultaneously screen for qualitative, quantitative, and kinetic information on protein bindings/interactions in a single assay, at once. Bharath is also the inventor of FENT solid-state nanopore technology for 1000x faster DNA sequencing at 1/10th cost, being developed by iNanoBio Inc. He raised $18M private capital and secured about $8M from DARPA, NIH. Bharath’s vision is to achieve 90% disease preemption, which is to detect and intervene in pre-disease phases, to cure before full disease onset.

... read more

Bharath Takulapalli, PhD

Founder & CEO
SPOC Biosciences

Bharath is inventor of multiple foundational life science technologies at the interface of nanotechnology, systems biology and ML/AI, to extract 100x more information from systems biology than currently possible. He conceived Sensor-integrated Proteome On Chip (SPOC) technology to bridge a big gap in proteomics space, to democratize high-throughput functional protein screening. SPOC is the first and only technology that enables production of 1000s of full-length folded proteins on 1.5 sq-cm biosensor chips, to simultaneously screen for qualitative, quantitative, and kinetic information on protein bindings/interactions in a single assay, at once. Bharath is also the inventor of FENT solid-state nanopore technology for 1000x faster DNA sequencing at 1/10th cost, being developed by iNanoBio Inc. He raised $18M private capital and secured about $8M from DARPA, NIH. Bharath’s vision is to achieve 90% disease preemption, which is to detect and intervene in pre-disease phases, to cure before full disease onset.

  • Hear cross-functional perspectives on successfully implementing AI across process development teams, from aligning with quality, IT, and manufacturing to overcoming cultural and technical barriers, with a focus on driving operational efficiency and long-term value.

Author:

Justin Byers

Founder and Chief Executive Officer
Axio BioPharma

Justin Byers is the Founder and Chief Executive Officer of Axio BioPharma, an AI biomanufacturing company revolutionizing how monoclonal antibodies are developed and produced. Based in Madison, Wisconsin, Axio launched in 2024 with a mission to accelerate and de-risk the development of recombinant proteins and monoclonal antibodies through AI-driven process design and U.S.-based manufacturing.

Under Justin’s leadership, Axio has pioneered a data-rich, machine learning–powered approach that reduces process development timelines from years to days unlocking faster, more cost-efficient pathways for biotech partners. He has steered the company’s rapid growth, from establishing its state-of-the-art facilities to securing strategic partnerships, including collaborations to advance next-generation drug delivery technologies.

With a background at the intersection of biomanufacturing, technology, and entrepreneurship, Justin brings a vision of scaling biologics development with speed, reliability, and accessibility. He is committed to building Axio into a trusted partner for innovators worldwide, combining scientific rigor with cutting-edge AI to bring life-changing therapies to patients faster.

... read more

Justin Byers

Founder and Chief Executive Officer
Axio BioPharma

Justin Byers is the Founder and Chief Executive Officer of Axio BioPharma, an AI biomanufacturing company revolutionizing how monoclonal antibodies are developed and produced. Based in Madison, Wisconsin, Axio launched in 2024 with a mission to accelerate and de-risk the development of recombinant proteins and monoclonal antibodies through AI-driven process design and U.S.-based manufacturing.

Under Justin’s leadership, Axio has pioneered a data-rich, machine learning–powered approach that reduces process development timelines from years to days unlocking faster, more cost-efficient pathways for biotech partners. He has steered the company’s rapid growth, from establishing its state-of-the-art facilities to securing strategic partnerships, including collaborations to advance next-generation drug delivery technologies.

With a background at the intersection of biomanufacturing, technology, and entrepreneurship, Justin brings a vision of scaling biologics development with speed, reliability, and accessibility. He is committed to building Axio into a trusted partner for innovators worldwide, combining scientific rigor with cutting-edge AI to bring life-changing therapies to patients faster.

  • Integrating AI and decision science to design faster, smarter, lower-risk trials
  • • Using adaptive methods to boost efficiency and responsiveness in trial design
  • • Turning complex data into insights that accelerate timelines and improve outcomes

 

Author:

Tom Oliver

Head of Product
Faculty

Tom Oliver is Head of Product at Faculty, where he leads the strategy and roadmap for Faculty Frontier™, the company’s decision-intelligence platform that helps enterprises operationalize AI in day-to-day decisions. Tom partners with executives and cross functional teams, including product managers, engineers, data scientists, and designers, to discover, build, and scale products that solve real problems for technical and business users. He collaborates closely with Faculty’s leadership and with key stakeholders and clients across pharma, retail, consumer goods, and healthcare, turning complex challenges into measurable outcomes. Before joining Faculty, Tom held leadership positions at PwC, focusing on technology enabled transformation, operating model change, and enterprise technology selection and deployment. His public writing explores the future of work, AI ethics, and human centric design, asking how powerful systems can advance human flourishing, not only efficiency. He holds a degree from the University of Oxford.

... read more

Tom Oliver

Head of Product
Faculty

Tom Oliver is Head of Product at Faculty, where he leads the strategy and roadmap for Faculty Frontier™, the company’s decision-intelligence platform that helps enterprises operationalize AI in day-to-day decisions. Tom partners with executives and cross functional teams, including product managers, engineers, data scientists, and designers, to discover, build, and scale products that solve real problems for technical and business users. He collaborates closely with Faculty’s leadership and with key stakeholders and clients across pharma, retail, consumer goods, and healthcare, turning complex challenges into measurable outcomes. Before joining Faculty, Tom held leadership positions at PwC, focusing on technology enabled transformation, operating model change, and enterprise technology selection and deployment. His public writing explores the future of work, AI ethics, and human centric design, asking how powerful systems can advance human flourishing, not only efficiency. He holds a degree from the University of Oxford.

Author:

Tarun Walia

Senior Director, Decision Science
Novo Nordisk
... read more

Tarun Walia

Senior Director, Decision Science
Novo Nordisk

Author:

Stephanie Vakaljan

Director of Trial Analytics and Decision Support
GSK
... read more

Stephanie Vakaljan

Director of Trial Analytics and Decision Support
GSK
  • Learn how real-world data is transformed into structured, usable intelligence through PRISM (Patient Record Inference & Structuring Module), an AI-enabled engine that converts fragmented, multi-modal patient data into inference-ready patient journeys supporting scalable clinical insights and model validation.

  • Explore how Zephyr’s AI-enabled multi-modal models (AIM Suite) predict drug response and reconstruct gene expression from clinically available inputs, such as NGS data from commercial LDTs and whole-slide images, enabling retrospective and prospective evaluation of treatment predictions across oncologic therapeutic classes.

  • Discover how Zephyr’s AI-driven software accelerates co-development and clinical integration, enabling fine-tuned foundation models to embed directly into R&D workflows while supporting rapid clinical intelligence queries, cohorting, and data-driven decision-making.

Author:

Anshu Jain, MD

Chief Business and Clinical Officer
Zephyr AI

Dr. Anshu Jain is Zephyr AI’s Chief Business and Clinical Officer. A double board-certified radiation oncologist and clinical informatician, he leads business development, clinical strategy, medical affairs, and partner collaborations—translating Zephyr’s AI and large-scale real-world data into solutions that help biopharma and diagnostic partners advance precision medicine for patients. Prior to Zephyr, Dr. Jain served as Chief Medical Officer at Aster Insights.

Dr. Jain has authored peer-reviewed publications in Nature Communications, Journal of Clinical Oncology (JCO), and JCO Clinical Cancer Informatics, and has served as a principal investigator for early- and late-phase oncology trials. He has advised the FDA Office of the Commissioner and the Oncology Center of Excellence, and provided clinical leadership to large-scale data initiatives including the NCI SEER program.

He serves on the Board of Directors of the Community Oncology Alliance, the Board of Advisors for the Duke Cancer Institute, and is an Assistant Professor at the Yale School of Medicine.

Dr. Jain trained in internal medicine and radiation oncology at the Massachusetts General Hospital and Columbia New York Presbyterian Hospital. He earned his M.D. with Highest Distinction from the University of Kentucky College of Medicine and a degree in Economics from Duke University.

... read more

Anshu Jain, MD

Chief Business and Clinical Officer
Zephyr AI

Dr. Anshu Jain is Zephyr AI’s Chief Business and Clinical Officer. A double board-certified radiation oncologist and clinical informatician, he leads business development, clinical strategy, medical affairs, and partner collaborations—translating Zephyr’s AI and large-scale real-world data into solutions that help biopharma and diagnostic partners advance precision medicine for patients. Prior to Zephyr, Dr. Jain served as Chief Medical Officer at Aster Insights.

Dr. Jain has authored peer-reviewed publications in Nature Communications, Journal of Clinical Oncology (JCO), and JCO Clinical Cancer Informatics, and has served as a principal investigator for early- and late-phase oncology trials. He has advised the FDA Office of the Commissioner and the Oncology Center of Excellence, and provided clinical leadership to large-scale data initiatives including the NCI SEER program.

He serves on the Board of Directors of the Community Oncology Alliance, the Board of Advisors for the Duke Cancer Institute, and is an Assistant Professor at the Yale School of Medicine.

Dr. Jain trained in internal medicine and radiation oncology at the Massachusetts General Hospital and Columbia New York Presbyterian Hospital. He earned his M.D. with Highest Distinction from the University of Kentucky College of Medicine and a degree in Economics from Duke University.

Data powers the engine of artificial intelligence (AI), but not all data is created equal. While software capabilities are rapidly accelerating, the biopharma industry still largely lacks the intelligent hardware needed to generate clean, contextualized, and high-quality data that AI and machine learning (ML) models require to deliver on their promise.

Explore how today’s in silico process development tools for bioreactor scaling and mechanistic modeling of chromatography can help you get it right the first time now, and why the next generation of intelligent hardware will be critical to unlocking the full potential of AI/ML in biopharma.

Author:

Tobias Hahn, PhD

R&D Director, GoSilico
Cytiva

Tobias Hahn is R&D Director of chromatography mechanistic modeling activities at Cytiva. As former co-founder and CEO of GoSilico, now part of Cytiva, Tobias is responsible for delivering simulation software and workflows for in silico process development. He received his undergraduate education in computational mathematics and technical physics in Karlsruhe and Stockholm, earning his PhD in chemical engineering from Karlsruhe Institute of Technology (KIT). During his doctoral studies, he utilized his background in mathematics and software engineering to create the simulation software now known as GoSilico™ chromatography modeling software.

... read more

Tobias Hahn, PhD

R&D Director, GoSilico
Cytiva

Tobias Hahn is R&D Director of chromatography mechanistic modeling activities at Cytiva. As former co-founder and CEO of GoSilico, now part of Cytiva, Tobias is responsible for delivering simulation software and workflows for in silico process development. He received his undergraduate education in computational mathematics and technical physics in Karlsruhe and Stockholm, earning his PhD in chemical engineering from Karlsruhe Institute of Technology (KIT). During his doctoral studies, he utilized his background in mathematics and software engineering to create the simulation software now known as GoSilico™ chromatography modeling software.

Author:

Cilon Li

Sr. Director of Engineering, Digital Products Development
Cytiva

Cilon Li is a digital and IT executive with over 15 years of experience in healthcare and biopharma. He is a strategic leader with a proven track record in driving digital transformation across supply chain management, product management, and R&D. At Cytiva, Cilon drives the company’s digital strategy and expanding product portfolio, encompassing Internet of Things (IoT), data analytics, AI/ML, software as a service (SaaS) and enterprise applications to help customers progress their digital biomanufacturing journeys. 

... read more

Cilon Li

Sr. Director of Engineering, Digital Products Development
Cytiva

Cilon Li is a digital and IT executive with over 15 years of experience in healthcare and biopharma. He is a strategic leader with a proven track record in driving digital transformation across supply chain management, product management, and R&D. At Cytiva, Cilon drives the company’s digital strategy and expanding product portfolio, encompassing Internet of Things (IoT), data analytics, AI/ML, software as a service (SaaS) and enterprise applications to help customers progress their digital biomanufacturing journeys. 

Review how decision intelligence is transforming the way organisations plan and execute complex projects. Apply decision intelligence to high-stakes environments such as clinical trials and learn how AI can dramatically reduce trial-planning timelines, optimise trial execution, and improve portfolio-level decision-making. Explore how leading enterprises are using Decision Intelligence platform to bring greater clarity, speed, and confidence to their most critical operational and strategic decisions.

Author:

Andrew Brookes

Chief Technical Officer & Co-Founder
Faculty

Andrew leads Faculty’s technical teams and developed the backbone of Faculty’s AI operating system, Frontier. His accomplishments span building the NHS Covid Early Warning System and mission critical projects for the UK Ministry of Defence. Before Faculty, Andrew led an engineering team at investment management firm BlackRock. He holds a Master’s degree in Computer Science from the University of Warwick.

 

... read more

Andrew Brookes

Chief Technical Officer & Co-Founder
Faculty

Andrew leads Faculty’s technical teams and developed the backbone of Faculty’s AI operating system, Frontier. His accomplishments span building the NHS Covid Early Warning System and mission critical projects for the UK Ministry of Defence. Before Faculty, Andrew led an engineering team at investment management firm BlackRock. He holds a Master’s degree in Computer Science from the University of Warwick.

 

This session explores how hybrid AI infrastructure is transforming drug discovery by integrating on-premises, private cloud, and public cloud resources for optimal data control, computational power, scalability, and security. Attendees will learn how pharmaceutical organizations use cutting-edge AI and machine learning tools for target identification and molecular design, while maintaining compliance with strict regulatory standards. The presentation will cover the architecture and core components of hybrid infrastructure, including high-performance computing, data management, MLOps, and compliance frameworks. Key benefits such as accelerated R&D, cost reduction, improved collaboration, and flexible scalability will be discussed, alongside real-world case studies. The session will also address challenges like data integration, interoperability, regulatory complexity, and AI interpretability, offering practical strategies to overcome these obstacles.

Author:

Alex Madama

Distinguished Technologist
Hewlett Packard Enterprise

Alex Madama is a Distinguished Technologist at Hewlett Packard Enterprise, specializing in strategic technology integration for life sciences organizations, including healthcare, pharmaceutical, biotech, and medical device companies. He leads initiatives combining high-performance computing, Hybrid Cloud, IoT, big data, and AI to advance drug discovery, pharmaceutical R&D, and biologics manufacturing, aiming to optimize patient outcomes and reduce costs. Before re-joining HPE, Alex served as Vice President of Product at UnitedHealth Group R&D, where he drove innovation in healthcare research and development. He holds a bachelor’s degree in life science and a Doctor of Osteopathic Medicine from New York Institute of Technology, with additional clinical training at Good Samaritan Hospital Medical Center, and lectures as an Adjunct Professor of Health Information Technology at Hofstra University. Previously, Alex founded Onyx CCS and held leadership roles at Nook.com, Barnes & Noble, AIG, Cravath Swaine & Moore, and as founder of seekPhysician.com.

... read more

Alex Madama

Distinguished Technologist
Hewlett Packard Enterprise

Alex Madama is a Distinguished Technologist at Hewlett Packard Enterprise, specializing in strategic technology integration for life sciences organizations, including healthcare, pharmaceutical, biotech, and medical device companies. He leads initiatives combining high-performance computing, Hybrid Cloud, IoT, big data, and AI to advance drug discovery, pharmaceutical R&D, and biologics manufacturing, aiming to optimize patient outcomes and reduce costs. Before re-joining HPE, Alex served as Vice President of Product at UnitedHealth Group R&D, where he drove innovation in healthcare research and development. He holds a bachelor’s degree in life science and a Doctor of Osteopathic Medicine from New York Institute of Technology, with additional clinical training at Good Samaritan Hospital Medical Center, and lectures as an Adjunct Professor of Health Information Technology at Hofstra University. Previously, Alex founded Onyx CCS and held leadership roles at Nook.com, Barnes & Noble, AIG, Cravath Swaine & Moore, and as founder of seekPhysician.com.

Advanced computing is a strategic imperative for pharmaceutical innovation. The industry is at a point where traditional computational methods are no longer sufficient to solve the increasingly complex problems in R&D and operations. Embracing technologies like quantum computing and HPC is critical for maintaining a competitive edge and driving breakthroughs.

A hybrid approach is essential for a complete solution. No single technology is the silver bullet. The most effective solutions come from using the right tools—be it classical, quantum, or quantum-inspired—and combining them into a single, powerful workflow to maximize efficiency and impact. This approach allows companies to apply the best technology to a wide range of problems across the business, not just in drug discovery.

Strategic partnerships are key to capability building. For a large enterprise like J&J, the path to adopting these advanced technologies is best navigated through collaboration. Working with a specialist like Strangeworks bridges the knowledge gap, provides access to powerful platforms, and helps overcome organizational hurdles. The ultimate goal of this collaborations like these is to be able to empower J&J's internal teams to become self-sufficient pioneers of innovation.

Author:

Steve Gibson

Chief Commercial Officer
Strangeworks

Steve has held a range of C-Suite positions in technology companies ranging from financial technology services, to data science consulting. Currently he serves as Chief Commercial Officer at Strangeworks; an advanced compute platform as a service (PaaS) company based in Austin, Texas. Prior to Strangeworks, Steve helped build several startups from the ground up, the most successful being Honest Dollar which was the first startup acquired by Goldman Sachs in their 147 year history. Prior to Honest Dollar, Steve worked for a number of large multinational corporations in the European aerospace sector delivering platforms for military, civil and space applications. Steve holds a Bachelor’s degree in Aerospace Systems Engineering from the University of Coventry in the UK.

... read more

Steve Gibson

Chief Commercial Officer
Strangeworks

Steve has held a range of C-Suite positions in technology companies ranging from financial technology services, to data science consulting. Currently he serves as Chief Commercial Officer at Strangeworks; an advanced compute platform as a service (PaaS) company based in Austin, Texas. Prior to Strangeworks, Steve helped build several startups from the ground up, the most successful being Honest Dollar which was the first startup acquired by Goldman Sachs in their 147 year history. Prior to Honest Dollar, Steve worked for a number of large multinational corporations in the European aerospace sector delivering platforms for military, civil and space applications. Steve holds a Bachelor’s degree in Aerospace Systems Engineering from the University of Coventry in the UK.

Author:

Selene Sass

Technology Product Manager
Johnson and Johnson

Selene is a technology product manager at Johnson & Johnson with nearly five years supporting the Advanced Computing and Analytics team. Her primary focus is to empower R&D scientists with emerging and innovative technologies in the advanced computing space, including the integration of quantum computing within J&J. Currently, she supports groups working in AI/ML and is exploring how quantum computing techniques can further enhance these capabilities. 

... read more

Selene Sass

Technology Product Manager
Johnson and Johnson

Selene is a technology product manager at Johnson & Johnson with nearly five years supporting the Advanced Computing and Analytics team. Her primary focus is to empower R&D scientists with emerging and innovative technologies in the advanced computing space, including the integration of quantum computing within J&J. Currently, she supports groups working in AI/ML and is exploring how quantum computing techniques can further enhance these capabilities.